DEA should remove barriers to opioid use disorder treatment
BCHC submitted comments to DEA about the proposed rule on the Expansion of Induction of Buprenorphine via Telemedicine Encounter.
BCHC urges DEA to:
eliminate the in-person evaluation when prescribing more than a 30-day supply of buprenorphine via telemedicine and to promulgate consistent policies across federal agencies;
promulgate a rule to allow prescribing of buprenorphine via telehealth permanently;
develop consistency across clinical settings and providers in reporting to prescription drug monitoring programs (PDMPs).
Read the full commentDownload now Read the full comment